Triptorelin GnRH Peptide
Swap one D-tryptophan into position six of GnRH and you get a superagonist thirteen times stronger in rats. It ended up shutting the axis down, not up, and that inversion is the whole story.
Choose your pack
For research use only. Not for human or veterinary use.
What Triptorelin GnRH Peptide is
The plain-language version, first.
GnRH with one residue flipped to its mirror image, and consequences.
Triptorelin is a synthetic decapeptide GnRH agonist with the sequence pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2, differing from gonadorelin only by substitution of D-tryptophan for glycine at position six, with free base formula C64H82N18O13, molecular weight 1311.4 and CAS number 57773-63-4. Continuous receptor occupancy from depot formulations desensitises pituitary GnRH receptors and suppresses gonadotropin secretion, and triptorelin is authorised in Canada as a prescription product under DINs including 02389282 and 02240000.
One substitution. Position six. A D-tryptophan, the mirror-image form, dropped into GnRH's ten residues.
Result: a molecule about thirteen times more potent in the classic rat assays, and far more resistant to being cleared.
You would predict a stronger, longer version of the natural signal. Endocrinology had other plans.
Because this axis reads rhythm rather than volume, a signal that will not go away is not a louder message. It is a jammed frequency.
Triptorelin is what happens when you win the potency contest and lose the rhythm. The axis's response is the interesting part.
triptorelin GnRH agonist mechanism
Mechanism studied, not outcome promised.
Glycine out, D-tryptophan in. The D form is the mirror image of what peptidases are built to cut, so the molecule survives where native GnRH gets chopped in half. Everything else in the sequence is untouched.
An agonist agonises first. LH and FSH rise early, then sustained occupancy downregulates the receptor and output drops below where it started. That initial rise is the mechanism working, not a fault in it.
Rung once an hour, the pituitary keeps answering. Held down, it stops. Belchetz and colleagues showed that in 1978 and credited the pattern of delivery rather than the amounts.
A stronger signal that produces silence. The axis's best paradox.
Recall the gonadorelin rule: pulses run the axis, continuous exposure shuts it down.
Triptorelin is that rule weaponised. Sustained receptor occupancy produces a brief initial surge, then downregulation, and the whole downstream axis goes quiet.
A superagonist that functions as a suppressor. Pharmacology's best-known judo throw.
This is not a side effect. It is the entire clinical point: where medicine wants the reproductive axis off, long-acting GnRH agonists are how it is done, deliberately, under supervision.
Here's the honest part for anybody reading this page with the opposite outcome in mind.
The molecule's documented, approved, decades-established action is suppression. Any use imagined in the other direction is fighting the mechanism itself.
The research so far for Triptorelin GnRH Peptide
Where the evidence is thin, we say so.
FDA approvals for Trelstar, NDA 020715 in 2000, and Triptodur, NDA 208956 in 2017. Marketed Health Canada DINs 02389282 for Decapeptyl and 02240000, 02243856 and 02412322 for Trelstar, all prescription. The 1976 Journal of Medicinal Chemistry paper reporting D-Trp6 LH-RH at thirteen times the activity of LH-RH, and the 1978 Science paper establishing that pattern beats amount.
Any of that transferring to a research vial. The clinical file belongs to specific depot formulations with defined release profiles, not to lyophilised powder sitting on a bench. There's no ambiguity on the sport side either, since WADA names triptorelin outright in section S2.2.1 of the Prohibited List.
The defining experiment for this molecular class is Belchetz, Plant, Nakai, Keogh and Knobil, Science 1978, PMID 100883, conducted in rhesus monkeys with hypothalamic lesions that eliminated endogenous GnRH input and left exogenous delivery as the only variable. Intermittent administration at one pulse per hour reestablished pituitary gonadotropin secretion, whereas continuous infusion failed to restore sustained secretion, and the authors attribute the difference to the pattern of GnRH delivery rather than to the amounts administered, noting that continuous administration can result in desensitisation or down regulation. Triptorelin's clinical utility follows directly from that result. Substituting D-tryptophan at position six confers resistance to enzymatic cleavage, and depot formulation extends exposure further, so the receptor is held in the continuous condition rather than the pulsatile one. The consequence is suppression of the hypothalamic pituitary gonadal axis after an initial agonist surge, which is the basis of its use in advanced prostate cancer and central precocious puberty. One receptor, opposite endocrine outcomes, decided by the temporal pattern of occupancy.
A real approved drug elsewhere, used precisely because it suppresses.
This is an approved pharmaceutical in many countries, in long-acting depot formulations, used clinically for exactly the suppression described above.
Decades of real human data exist, all of it belonging to those supervised depot products in defined conditions.
The file is deep, and it is a file about switching an axis off. There is no parallel literature about casual or research use in the other direction.
Prohibited in sport, category S2.
One of the best-understood molecules on this shelf, and understood to do the opposite of what most people arriving at this page expect. We would rather say that in the first paragraph than let the potency number mislead you.
Triptorelin · lyophilised powder · sealed vial · Canadian stock, ships from BC
Triptorelin GnRH Peptide specs
The chemistry, exactly as released.
Who studies Triptorelin GnRH Peptide
Who tends to order this one, and why.
A research compound does not have one audience. It has a handful of rooms where the same question keeps coming up, and the question is a different question in each of them.
Endocrine axis research
Groups working the hypothalamic pituitary gonadal axis who need an agonist that stays put, rather than a native ligand that's gone before the next timepoint.
Receptor desensitisation studies
Bench work on GPCR downregulation, where GnRHR is one of the cleanest systems available for showing that exposure pattern can flip the sign of a response.
Comparative analogue work
Side by side studies against gonadorelin, where the only variable is one D amino acid at position six and the other nine residues hold perfectly still.
Analytical method development
Mass spec and assay work that has to account for both the free base mass and the pamoate salt mass, which is a reliably common place for a spreadsheet to go wrong.
Sold for laboratory research only. This is not guidance for personal use, and nothing here is a recommendation.
Triptorelin GnRH Peptide backstory
How it got here.
Schally's lab had already spent a decade proving what GnRH was. The obvious next move was to build a better one, and in 1976 better meant stronger.
The trick they reached for is one of the oldest in peptide chemistry. Your enzymes evolved to recognise L amino acids, because that's what proteins are made of.
Hand them a D amino acid, the mirror image, and the scissors don't close properly. Put that D residue exactly where the peptide normally gets cut, which for GnRH is position six, and the molecule survives a great deal longer in circulation.
Coy, Vilchez-Martinez, Coy and Schally reported the result in 1976. Thirteen times more active than LH-RH itself in immature male rats.
A superagonist, on purpose. The part nobody planned for is what the field did with it.
Within a few years urologists and paediatric endocrinologists were using it not to turn the axis up but to shut it off, because sustained stimulation of that receptor produces the opposite of pulsed stimulation. The most potent fertility signal anybody had synthesised became a fertility suppressant.
Same molecule, different clock.
- 1
1976, the superagonist
Coy, Vilchez-Martinez, Coy and Schally report D-Trp6 LH-RH at thirteen times the activity of LH-RH itself in immature male rats. The goal was more signal.
- 2
1978, the twist
Belchetz and colleagues show in lesioned rhesus monkeys that hourly pulses sustain gonadotropin secretion while continuous infusion does not. The pattern, not the amount.
- 3
2000 and 2017, the depots
Trelstar clears FDA under NDA 020715, Triptodur follows seventeen years later. Both are engineered to keep exposure continuous, which is how a stimulator ends up working as a suppressor.
Buying Triptorelin GnRH Peptide in Canada
What ships, how fast, and the paperwork.
The hard part of buying research material is almost never the compound. It is the logistics. What leaves the building, how fast it moves, and what is in the box beside the vial. Here is ours, plainly.
It's a prescription drug here, and this isn't it
Triptorelin depot products carry live Health Canada DINs and sit on the Prescription Drug List. This vial is a research reagent for laboratory use. Not the approved medicine, not a depot formulation, and not sold for use in people or animals.
Named on the WADA list
Section S2.2.1 spells out triptorelin by name, prohibited at all times. Tested athletes should treat it that way, and no amount of research framing changes what the list says.
Ships domestic
Stock sits in British Columbia and orders leave from there. Lyophilised powder in a sealed vial, and no border between us and you.
Stuff people ask about Triptorelin GnRH Peptide
If your question is not here, email us. Real human answers.
A GnRH analogue, which really means gonadorelin with one change. The decapeptide reads pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2, with D-tryptophan replacing glycine at position six. Free base formula C64H82N18O13, molecular weight 1311.4, CAS 57773-63-4. That single substitution is what makes it resistant to the enzymes that clear native GnRH in a matter of minutes.
Because the receptor responds to timing and not just to occupancy. Pulsed stimulation keeps gonadotropin secretion running, while continuous stimulation desensitises and downregulates the receptor until output falls below where it started. Belchetz and colleagues demonstrated exactly that in Science in 1978. Depot formulations of triptorelin are engineered to hold the continuous condition, so a stimulator behaves like a suppressor.
Yes. Health Canada shows marketed DINs 02389282 for Decapeptyl from Ferring and 02240000, 02243856 and 02412322 for Trelstar from Knight, all of them prescription. FDA approved Trelstar under NDA 020715 in 2000 and Triptodur under NDA 208956 in 2017. Those approvals belong to specific depot products, not to the research vial on this page.
Position six. Gonadorelin has glycine there and is identical to your own GnRH. Triptorelin has D-tryptophan and lasts far longer. That difference in duration flips the outcome, because a short signal reads as a pulse and a long one reads as continuous. One of them turns the reproductive axis on, the other one eventually turns it off.
Yes, named explicitly in section S2.2.1 of the WADA Prohibited List, sitting right alongside gonadorelin. That category covers agents affecting the hypothalamic pituitary gonadal axis, and triptorelin is one of the compounds spelled out by name rather than swept in under a catch all clause. If you're tested, that's your answer.
Because you're reading two different forms of the same thing. The free base comes out at 1311.4, while the Trelstar label lists the pamoate salt at 1699.9. Add pamoic acid at 388.38 to 1311.47 and you land on 1699.85, which is the same number once you allow for rounding. Neither source is wrong, they're describing different material.
Good pairing options with Triptorelin GnRH Peptide
What researchers stack alongside it.
Pairing is where research gets ahead of itself. These are the compounds researchers put in the same order as Triptorelin GnRH Peptide, which is a statement about ordering habits, not about evidence. Two things in one cart have not been studied together unless somebody studied them together.
Not a molecule. FSH and LH activity extracted from postmenopausal urine and standardised in international units. Still marketed in Canada in 2026, which makes it the rare extract with live approvals.
The unprocessed precursor, all 344 residues with the signal peptide still attached. The protein your body actually secretes is a different animal: 315 residues and 36 cysteines folded just so.
Order Triptorelin GnRH Peptide right now
One last look before you decide.
Freeze-dried, COA on the page, ships cold
If you are researching Triptorelin GnRH Peptide and you want a source you do not have to second-guess, start with the paperwork on this page. For research use only.
Not for human consumption. Not approved by Health Canada or any other regulatory body.
Page last updated August 19, 2026
People also search for Triptorelin GnRH Peptide
Other names for the same compound.